Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2

J Virol. 2013 Dec;87(23):12552-61. doi: 10.1128/JVI.01890-13. Epub 2013 Sep 11.

Abstract

The Middle East respiratory syndrome coronavirus (MERS-CoV) utilizes host proteases for virus entry into lung cells. In the current study, Vero cells constitutively expressing type II transmembrane serine protease (Vero-TMPRSS2 cells) showed larger syncytia at 18 h after infection with MERS-CoV than after infection with other coronaviruses. Furthermore, the susceptibility of Vero-TMPRSS2 cells to MERS-CoV was 100-fold higher than that of non-TMPRSS2-expressing parental Vero cells. The serine protease inhibitor camostat, which inhibits TMPRSS2 activity, completely blocked syncytium formation but only partially blocked virus entry into Vero-TMPRSS2 cells. Importantly, the coronavirus is thought to enter cells via two distinct pathways, one mediated by TMPRSS2 at the cell surface and the other mediated by cathepsin L in the endosome. Simultaneous treatment with inhibitors of cathepsin L and TMPRSS2 completely blocked virus entry into Vero-TMPRSS2 cells, indicating that MERS-CoV employs both the cell surface and the endosomal pathway to infect Vero-TMPRSS2 cells. In contrast, a single camostat treatment suppressed MERS-CoV entry into human bronchial submucosal gland-derived Calu-3 cells by 10-fold and virus growth by 270-fold, although treatment with both camostat and (23,25)-trans-epoxysuccinyl-L-leucylamindo-3-methylbutane ethyl ester, a cathepsin inhibitor, or treatment with leupeptin, an inhibitor of cysteine, serine, and threonine peptidases, was no more efficacious than treatment with camostat alone. Further, these inhibitors were not efficacious against MERS-CoV infection of MRC-5 and WI-38 cells, which were derived from lung, but these characters differed from those of mature pneumocytes. These results suggest that a single treatment with camostat is sufficient to block MERS-CoV entry into a well-differentiated lung-derived cell line.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / administration & dosage
  • Cell Line
  • Cell Membrane / enzymology*
  • Cell Membrane / virology
  • Coronavirus / drug effects
  • Coronavirus / physiology*
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / enzymology*
  • Coronavirus Infections / virology
  • Esters
  • Gabexate / administration & dosage
  • Gabexate / analogs & derivatives
  • Giant Cells / drug effects
  • Giant Cells / virology
  • Guanidines
  • Humans
  • Serine Endopeptidases / metabolism*
  • Serine Proteinase Inhibitors / administration & dosage
  • Virus Internalization / drug effects

Substances

  • Antiviral Agents
  • Esters
  • Guanidines
  • Serine Proteinase Inhibitors
  • camostat
  • Gabexate
  • Serine Endopeptidases
  • TMPRSS2 protein, human